

CLAIMS

1. Use of a retinoic acid antagonist in the manufacture of a medicament for the treatment or prevention of Barrett's oesophagus (Barrett's mucosa).
- 5 2. Use of a retinoic acid antagonist in the manufacture of a medicament for the treatment or prevention of ectopic development of columnar epithelium.
3. Use of a retinoic acid antagonist in the conversion of columnar epithelium to squamous epithelium.
- 10 4. Use of a retinoic acid antagonist in the induction or maintenance of squamous epithelium.
5. Use of a retinoic acid antagonist in the reduction of proliferation of ectopic
15 columnar epithelium.
6. Use of a retinoic acid antagonist in the downregulation of CYP26A1.
7. A use according to any preceding claim wherein the retinoic acid antagonist is
20 an aldehyde dehydrogenase inhibitor.
8. A use according to claim 7 wherein the aldehyde dehydrogenase inhibitor is a competitive inhibitor of aldehyde dehydrogenase.
- 25 9. A use according to any preceding claim wherein the retinoic acid antagonist is citral.
10. A use according to any preceding claim wherein the retinoic acid antagonist is a retinoic acid receptor antagonist.
- 30

11. A method of treating Barrett's oesophagus in a subject comprising administering to said subject an effective amount of retinoic acid antagonist.
12. A method of treating Barrett's oesophagus in a subject comprising
5 administering to said subject an effective amount of a CYP26A1 inhibitor.
13. A method according to claim 11 or claim 12 wherein said antagonist comprises citral.
- 10 14. Use of an inhibitor of CYP26A1 activity in the manufacture of a medicament for the treatment or prevention of Barrett's oesophagus (Barrett's mucosa).
- 15 15. Use of retinoic acid in the induction or maintenance of columnar epithelium.
16. Use of retinoic acid in the conversion of squamous epithelium to columnar epithelium.
17. A method, use or medicament substantially as described herein with reference to the accompanying figures.